| # | Title | Journal | Year | Citations |
|---|
| 1 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1,728 |
| 2 | An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer | Journal of Clinical Oncology | 2003 | 1,551 |
| 3 | Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial | Lancet, The | 2019 | 879 |
| 4 | American Society of Hematology 2019 guidelines for immune thrombocytopenia | Blood Advances | 2019 | 684 |
| 5 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial | Lancet Oncology, The | 2019 | 594 |
| 6 | Esophageal Carcinoma: Depth of Tumor Invasion Is Predictive of Regional Lymph Node Status | Annals of Thoracic Surgery | 1998 | 353 |
| 7 | Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck | Cancer | 2000 | 306 |
| 8 | Paclitaxel in cancer therapy | Expert Opinion on Pharmacotherapy | 2002 | 301 |
| 9 | Enteral nutrition during the treatment of head and neck carcinoma | Cancer | 2001 | 298 |
| 10 | Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes | Journal of Clinical Oncology | 2021 | 278 |
| 11 | Clinical Pharmacokinetics of Morphine | Therapeutic Drug Monitoring | 1991 | 249 |
| 12 | Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy | Archives of Internal Medicine | 2004 | 249 |
| 13 | International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease | Blood | 2018 | 232 |
| 14 | A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results | Head and Neck | 1997 | 218 |
| 15 | Intraperitoneal antineoplastic drug delivery: rationale and results | Lancet Oncology, The | 2003 | 208 |
| 16 | Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203) | Lancet Haematology,the | 2019 | 200 |
| 17 | Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer | JAMA Network Open | 2019 | 196 |
| 18 | Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome | Leukemia | 2004 | 185 |
| 19 | Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia | Blood | 2021 | 183 |
| 20 | A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation | Bone Marrow Transplantation | 2004 | 175 |
| 21 | Who merits a neck dissection after definitive chemoradiotherapy for N2–N3 squamous cell head and neck cancer? | Head and Neck | 2003 | 168 |
| 22 | The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma | Cancer | 2004 | 164 |
| 23 | Hypothyroidism | Cancer | 2001 | 158 |
| 24 | Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer | Urology | 2004 | 140 |
| 25 | Multiagent Concurrent Chemoradiotherapy for Locoregionally Advanced Squamous Cell Head and Neck Cancer: Mature Results From a Single Institution | Journal of Clinical Oncology | 2006 | 140 |
| 26 | Management of cancer‐associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH | Journal of Thrombosis and Haemostasis | 2018 | 140 |
| 27 | A genetic basis for the variation in the vulnerability of cancer to DNA damage | Nature Communications | 2016 | 136 |
| 28 | Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation | Head and Neck | 2006 | 134 |
| 29 | Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy | Annals of Oncology | 2006 | 132 |
| 30 | Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) | Blood Cancer Journal | 2020 | 131 |
| 31 | Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee | Biology of Blood and Marrow Transplantation | 2016 | 130 |
| 32 | A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience | Journal of Thoracic Oncology | 2009 | 126 |
| 33 | Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data | Oncologist | 2017 | 122 |
| 34 | Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline | Practical Radiation Oncology | 2019 | 121 |
| 35 | An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies | Blood Cancer Journal | 2015 | 117 |
| 36 | HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma | Clinical Cancer Research | 2020 | 117 |
| 37 | Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer | Proceedings of the National Academy of Sciences of the United States of America | 2015 | 115 |
| 38 | Maximizing Local Control and Organ Preservation in Stage IV Squamous Cell Head and Neck Cancer With Hyperfractionated Radiation and Concurrent Chemotherapy | Journal of Clinical Oncology | 2002 | 109 |
| 39 | Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma | Cancer | 1997 | 108 |
| 40 | Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study | Cancer Discovery | 2020 | 108 |
| 41 | Effect of Human Papillomavirus on Patterns of Distant Metastatic Failure in Oropharyngeal Squamous Cell Carcinoma Treated With Chemoradiotherapy | JAMA Otolaryngology - Head and Neck Surgery | 2015 | 104 |
| 42 | Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia | Blood | 2004 | 96 |
| 43 | Bleeding incidence and risk factors among cancer patients treated with anticoagulation | American Journal of Hematology | 2019 | 92 |
| 44 | Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 | Leukemia | 2003 | 90 |
| 45 | Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes | Journal of Clinical Oncology | 2021 | 90 |
| 46 | Management of angiosarcoma | Current Oncology Reports | 2002 | 89 |
| 47 | Ocular and Orbital Toxicity Following Intracarotid Injection of BCNU (Carmustine) and Cisplatinum for Malignant Gliomas | Ophthalmology | 1985 | 88 |
| 48 | Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation | Biology of Blood and Marrow Transplantation | 2016 | 87 |
| 49 | TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML | Blood Advances | 2020 | 85 |
| 50 | Phase II Trial of High-Dose Intermittent Interleukin-2 in Metastatic Renal Cell Carcinoma: A Southwest Oncology Group Study | Journal of the National Cancer Institute | 1990 | 84 |
